

IMMUNALL ANNOUNCES ELECTION OF NEW DIRECTORS AND OFFICER CHANGES

EDMONTON (Alberta, Canada) April 5, 2016 – Immunall Science Inc. (“**Immunall**” or the “**Company**”) (CSE: GNS) is pleased to announce that it held its annual general and special meeting on March 29, 2016 (the “**Meeting**”). At the Meeting, shareholders elected Dr. Jon-Paul Powers, Dr. Nils Rehmann, Mr. Stephane Maher, and Mr. Bret Smith to the Company’s board of directors (the “**Board**”). Shareholders also approved all other matters tabled at the Meeting, as set out in the Company’s management information circular dated February 26, 2016. Immunall will provide further details regarding the Company’s proposed name change, share consolidation, and continuation from Alberta into British Columbia in subsequent news releases when more information regarding those matters becomes available.

Dr. Powers, Dr. Rehmann, and Mr. Maher are new to the Board, and Mr. Smith has served as a director of Immunall since 2010. Following the election of Dr. Powers, Dr. Rehman, and Mr. Maher, Immunall reconstituted its Audit Committee to comprise Mr. Smith, Dr. Powers, and Mr. Maher. In addition, following the Meeting, Messrs. M. Frank Phillet and Craig McLennan stepped down as Chief Executive Officer (“**CEO**”) and Chief Financial Officer (“**CFO**”) of Immunall, respectively. Mr. Maher has been appointed as the Company’s new CEO, and will act as interim CFO until a successor for Mr. McLennan is appointed. Further details regarding each of the newly elected directors are set out below.

Since 2014, Dr. Powers has owned and operated Split Science Inc. (formerly Sixteen2 Inc.), a Canadian scientific and regulatory consultancy specializing in natural health products, foods, supplemented foods, cosmetics and pet supplements. Prior to founding Sixteen2 Inc., from 2009 to 2014, Dr. Powers acted as Director of Scientific Affairs at Body Plus Nutritional Products Inc. (“**Body Plus**”) and Sonoma Nutraceuticals Inc. (“**Sonoma**”). While at Body Plus and Sonoma, Dr. Powers oversaw all aspects of regulatory affairs pertaining to the manufacture and distribution of natural health products. Dr. Powers has also served as a Unit Head and Assessment Officer at the Natural Health Products Directorate of Health Canada and is currently a member of the Board of Directors of the Canadian Health Food Association (CHFA), Canada’s largest trade association dedicated to natural health and organic products. Dr. Powers received his Ph.D. in Microbiology from the University of British Columbia and a B.Sc. in Biochemistry from Carleton University. Dr. Powers’ academic background focused on studying the mechanism of action of cationic, antimicrobial peptides. In addition to a variety of publications and international patents, this work also resulted in the development of a new therapeutic agent that has shown positive preliminary results in Phase II clinical trials.

Since 2013, Dr. Rehmann has owned and operated NiRem Consulting Inc. (“**NiRem**”), a consulting company that advises clients in the biotechnology, research and development, and life sciences sectors on methods to improve laboratory performance, business development and regulatory compliance and assisting firms in achieving accreditation under International Standards Organization (ISO) and Good Manufacturing Practices (GMP). Prior to founding NiRem, Dr. Rehmann was a method development chemist for the Research and Productivity Council of New Brunswick from 2008 to 2013 where he was involved with developing nutritional labelling analysis and food safety regulatory analysis methods. Dr. Rehmann received his Ph.D. in Pharmacology and Toxicology from the University College Dublin, Ireland and a Chem.-Eng. degree from the University of Applied Sciences Fresenius, Germany. His academic work focused on extraction and purification of marine natural products from phytoplankton and facilitated new food safety protocols in the European Union, Asia and the Americas.

In 2002, Mr. Maher founded and has served as President of Yellow Brick Sales & Marketing Group Inc. (“**Yellow Brick**”), a consulting company that helps manufacturers, importers and retailers of food, cosmetics and natural health products to achieve regulatory compliance for Canada. Prior to establishing Yellow Brick, between 1999 and 2002, Mr. Maher was employed as Special Events Manager at Yves Veggie Cuisine (“**YVC**”), North American leader in the meat alternative category. While at YVC, Mr. Maher evaluated trade show opportunities (in both Canada and the United States), managed the logistics and marketing efforts for each trade show in order to maximize exposure and YVC’s return on its investment. Mr. Maher previously acted as Commercial Attaché for the Quebec Government Office in Vancouver, organizing trade missions to help Quebec based companies in establishing new markets in Western Canada, and promoting the Quebec Immigration Investor Program. Mr. Maher received his B.A. in Communication with minor in Marketing from Laval University in Quebec City.

Mr. Smith, the Company’s returning director, commented, “I am pleased to welcome the new members of the Board of Immunall Science Inc. This change in leadership marks a new chapter in Immunall’s development, and I envision the Company moving forward with new product innovations.”

On behalf of the Board,

Bret Smith
Director

Immunall Science Inc.
10979 – 127 Street
Edmonton, AB
Canada
T5M 0T1
780-718-6603

About Immunall Science Inc.

Immunall Science Inc. (CSE: GNS) is a company incorporated in Alberta and listed on the Canadian Securities Exchange (the “**CSE**”). The Company was involved in researching, developing, and commercializing technology relating to the growth and extraction of American ginseng. In 2014, Immunall ceased these business operations and is currently inactive.

The Canadian Securities Exchange has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-Looking Information

This news release includes certain information that may be deemed “forward-looking information”. Forward-looking information can generally be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “continue”, “plans” or similar terminology, or negative connotations thereof. All information in this release, other than information of historical facts, including, without limitation, Immunall’s proposed name change, share consolidation, and continuation from Alberta into British Columbia; and Immunall’s provision of more information regarding the Company’s proposed name change, share consolidation, and continuation from Alberta into British Columbia in subsequent news releases are forward-looking information that involve various risks and

uncertainties. Although the Company believes that the expectations expressed in such forward-looking information are based on reasonable assumptions, such expectations are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking information. Forward-looking information is based on a number of material factors and assumptions. Factors that could cause actual results to differ materially from the forward-looking information include the impact of general economic conditions, industry conditions, currency fluctuations, environmental risks, competition from industry participants, the lack of availability of qualified personnel or management, stock market volatility and ability to access sufficient capital from internal and external sources, and the inability to meet or continue to meet listing requirements on the Canadian Securities Exchange. Accordingly, actual events may differ materially from those projected in the forward-looking information. For more information on Immunall, investors should review the Company's continuous disclosure filings which are available at www.sedar.com. Readers are cautioned not to place undue reliance on forward-looking information. Immunall does not undertake to update any forward looking information, except in accordance with applicable securities laws.